TapewireFind a company

person · Reporting owner

Kamdar Kim P.

Disclosed activity across 8 companies

Tapewire entity
30494
SEC CIK
0001535065

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Bionano Genomics, Inc.BNGO · Entity 783110% ownerAugust 21, 2018August 21, 2018
Evofem Biosciences, Inc.EVFM · Entity 8607DirectorDecember 21, 2023December 22, 2023
SERA PROGNOSTICS, INC.SERA · Entity 304DirectorJuly 10, 2026July 14, 2026
Syndax Pharmaceuticals IncSNDX · Entity 4578Director · 10% ownerOctober 31, 2016November 02, 2016
Vyome Holdings, IncOBLN · Entity 1824DirectorSeptember 16, 2020September 18, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bionano Genomics, Inc.

Report date August 21, 2018 · Filed August 21, 2018

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, VITULLO NICOLE, Halak Brian K

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect140 Reported balance Holding disclosure · report date 2018-08-21 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 140

F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.20 · Expires 2019-05-10DirectNot disclosed Reported balance Holding disclosure · report date 2018-08-21 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2019-05-10DirectNot disclosed Reported balance Holding disclosure · report date 2018-08-21 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F2: The stock options are held by Brian K. Halak and are fully vested. Pursuant to the limited liability company agreement of Domain Associates, LLC, upon exercise 50% of the shares issued will be transferred to Domain Associates, LLC.

Evofem Biosciences, Inc.

Report date December 21, 2023 · Filed December 22, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-12-21 transaction · row 1
1 source row

Row 1 · 2023-12-21 · Sale · Disposed 10 · Balance 0

SERA PROGNOSTICS, INC.

Report date July 10, 2026 · Filed July 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect58,420 Ending reported balance After 2026-07-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-07-10 · Grant · Acquired 22,426 · Balance 54,999

F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Row 2 · 2026-07-10 · Grant · Acquired 3,421 · Balance 58,420

F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10Direct34,494 Reported balance After 2026-07-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-07-10 · Grant · Acquired 34,494 · Balance 34,494

F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10Direct5,263 Reported balance After 2026-07-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-07-10 · Grant · Acquired 5,263 · Balance 5,263

F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Syndax Pharmaceuticals Inc

Report date October 31, 2016 · Filed November 02, 2016

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2026-10-31Direct8,000 Reported balance After 2016-10-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2016-10-31 · Grant · Acquired 8,000 · Balance 8,000

Vyome Holdings, Inc

Report date September 16, 2020 · Filed September 18, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Expires 2030-09-16Direct27,250 Reported balance After 2020-09-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250

F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock.

F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2030-09-16Direct27,250 Reported balance After 2020-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250

F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock.

F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ocera Therapeutics, Inc.

Report date December 11, 2017 · Filed December 13, 2017

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, VITULLO NICOLE, Halak Brian K

Section 16 reporting ended · disclosed 2017-12-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2017-12-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2017-12-11 · Disposition to issuer · Disposed 47,963 · Balance 0

F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Singular Genomics Systems, Inc.

Report date February 21, 2025 · Filed February 25, 2025

Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-02-21 transaction · row 1
1 source row

Row 1 · 2025-02-21 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

Common StockSEC Table I · non-derivativeIndirectBy Domain Partners IX, L.P.0 Reported balance After 2025-02-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2025-02-21 · Disposition to issuer · Disposed 3,763,985 · Balance 0

F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Common StockSEC Table I · non-derivativeIndirectBy Domain Associates, LLC0 Reported balance After 2025-02-21 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2025-02-21 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05Direct0 Reported balance After 2025-02-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-02-21 · Disposition to issuer · Disposed 666 · Balance 0

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26Direct0 Reported balance After 2025-02-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25Direct0 Reported balance After 2025-02-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29Direct0 Reported balance After 2025-02-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 04, 2016

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, VITULLO NICOLE, Halak Brian K

Section 16 reporting ended · disclosed 2016-11-04. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2016-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2016-11-01 · Other · Disposed 38,094 · Balance 0

F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones.

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.00IndirectHeld by Jesse I. Treu0 Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2016-11-01 · Disposition to issuer · Acquired 1,996 · Balance 0

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.93IndirectHeld by Jesse I. Treu0 Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2016-11-01 · Disposition to issuer · Acquired 1,071 · Balance 0

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19IndirectHeld by Jesse I. Treu0 Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2016-11-01 · Disposition to issuer · Acquired 17,695 · Balance 0

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones.

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 10, 2026 Filed Jul 14, 2026 22:42 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 5,263 $0.00 Strike: $1.97 $0.00
Disclosure

SEC source: 0001535065-26-000002 · ownership.xml · derivative · entry 4

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,263

Underlying: Class A Common Stock · 5,263 shares

Expires 2036-07-10

F4 · derivative.exercise_date: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Read SEC document
July 10, 2026 Filed Jul 14, 2026 22:42 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 34,494 $0.00 Strike: $1.97 $0.00
Disclosure

SEC source: 0001535065-26-000002 · ownership.xml · derivative · entry 3

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,494

Underlying: Class A Common Stock · 34,494 shares

Expires 2036-07-10

F3 · derivative.exercise_date: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Read SEC document
July 10, 2026 Filed Jul 14, 2026 22:42 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantClass A Common Stock 3,421 $0.00 $0.00
Disclosure

SEC source: 0001535065-26-000002 · ownership.xml · nonDerivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,420

F2 · shares: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Read SEC document
July 10, 2026 Filed Jul 14, 2026 22:42 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantClass A Common Stock 22,426 $0.00 $0.00
Disclosure

SEC source: 0001535065-26-000002 · ownership.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,999

F1 · shares: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.

Read SEC document
February 04, 2026 Filed Feb 4, 2026 22:03 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 OtherClass A Common Stock 3,231 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-037807 · ownership.xml · nonDerivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,573

F2 · kind: Represents the pro rata distribution from Domain Associates, LLC, and not a purchase or sale, without additional consideration.

Read SEC document
February 04, 2026 Filed Feb 4, 2026 22:03 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 OtherClass A Common Stock 30,920 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-037807 · ownership.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Domain Associates, LLC

Disclosed balance after: 0

F1 · kind: Domain Associates, LLC distributed these shares to its members on a pro rata basis, for no consideration.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 22:39 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $1.60 $0.00
Disclosure

SEC source: 0000950170-25-083335 · ownership.xml · derivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2035-06-05

F2 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 22:39 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantClass A Common Stock 15,596 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083335 · ownership.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,342

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025, subject to the Reporting Person continuing to provide services to the issuer.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerStock Option (Right to Buy) · Derivative 2,466 $8.84 Strike: $11.16 $21,799.44
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · derivative · entry 7

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,466 shares

Expires 2034-05-29

F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerStock Option (Right to Buy) · Derivative 2,466 $0.00 Strike: $31.80 $0.00
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · derivative · entry 6

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,466 shares

Expires 2033-05-25

F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerStock Option (Right to Buy) · Derivative 1,541 $0.00 Strike: $85.80 $0.00
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · derivative · entry 5

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,541 shares

Expires 2032-05-26

F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerStock Option (Right to Buy) · Derivative 666 $0.00 Strike: $672.90 $0.00
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · derivative · entry 4

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 666 shares

Expires 2031-05-05

F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerCommon Stock 15,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · nonDerivative · entry 3

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Domain Associates, LLC

Disclosed balance after: 0

F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerCommon Stock 3,763,985 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · nonDerivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 0

F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

F2 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 20:05 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 Disposition to issuerCommon Stock 15,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-027096 · ownership.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").

Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:32 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 10,549 $0.00 Strike: $8.43 $0.00
Disclosure

SEC source: 0001534969-24-000133 · wk-form4_1717792311.xml · derivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,549

Underlying: Class A Common Stock · 10,549 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:32 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantClass A Common Stock 7,117 $0.00 $0.00
Disclosure

SEC source: 0001534969-24-000133 · wk-form4_1717792311.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,746

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer.

Read SEC document
May 29, 2024 Filed May 31, 2024 18:31 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 GrantStock Option (Right to Buy) · Derivative 74,000 $0.00 Strike: $0.37 $0.00
Disclosure

SEC source: 0000950170-24-067532 · ownership.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,000

Underlying: Common Stock · 74,000 shares

Expires 2034-05-29

F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025.

Read SEC document
December 21, 2023 Filed Dec 22, 2023 21:05 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 SaleCommon Stock 10 $0.62 $6.21
Disclosure

SEC source: 0001493152-23-045912 · ownership.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Read SEC document
August 15, 2023 Filed Aug 15, 2023 19:17 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 SaleCommon Stock 200,000 $0.53 $106,960.00
Disclosure

SEC source: 0001209191-23-045925 · doc4.xml · nonDerivative · entry 3

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 3,763,985

F1 · kind: Domain Partners IX, L.P. has been an investor in the Issuer since 2016 and continues to hold 3,763,985 shares of the Issuer's common stock.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 5 to this Form 4.

F3 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 19:17 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 SaleCommon Stock 77,991 $0.57 $44,423.67
Disclosure

SEC source: 0001209191-23-045925 · doc4.xml · nonDerivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 3,963,985

F1 · kind: Domain Partners IX, L.P. has been an investor in the Issuer since 2016 and continues to hold 3,763,985 shares of the Issuer's common stock.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.5821, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F3 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
August 11, 2023 Filed Aug 15, 2023 19:17 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 SaleCommon Stock 353,657 $0.60 $210,602.74
Disclosure

SEC source: 0001209191-23-045925 · doc4.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 4,041,976

F1 · kind: Domain Partners IX, L.P. has been an investor in the Issuer since 2016 and continues to hold 3,763,985 shares of the Issuer's common stock.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.58 to $0.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.

F3 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity; however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
June 08, 2023 Filed Jul 7, 2023 20:24 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 63,265 $0.00 Strike: $3.00 $0.00
Disclosure

SEC source: 0001534969-23-000081 · wk-form4_1688761482.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,265

Underlying: Class A Common Stock · 63,265 shares

Expires 2033-06-08

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 8, 2023.

Read SEC document
May 25, 2023 Filed May 26, 2023 17:06 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 GrantStock Option (Right to Buy) · Derivative 74,000 $0.00 Strike: $1.06 $0.00
Disclosure

SEC source: 0001209191-23-032609 · doc4.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,000

Underlying: Common Stock · 74,000 shares

Expires 2033-05-25

F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2024 Stockholder Annual Meeting or May 25, 2024.

Read SEC document
June 03, 2022 Filed Jun 6, 2022 20:58 UTC SERA PROGNOSTICS, INC. SERA · Entity 304 GrantStock Option (right to buy) · Derivative 149,675 $0.00 Strike: $1.35 $0.00
Disclosure

SEC source: 0001534969-22-000087 · wf-form4_165454910412913.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,675

Underlying: Class A Common Stock · 149,675 shares

Expires 2032-06-03

F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022.

Read SEC document
May 26, 2022 Filed May 31, 2022 21:01 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 GrantStock Option (Right to Buy) · Derivative 46,250 $0.00 Strike: $2.86 $0.00
Disclosure

SEC source: 0001209191-22-033017 · doc4.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,250

Underlying: Common Stock · 46,250 shares

Expires 2032-05-26

F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2023 Stockholder Annual Meeting or May 26, 2023.

Read SEC document
May 04, 2022 Filed May 6, 2022 20:10 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 GrantStock option (right to buy) · Derivative 6,000 $0.00 Strike: $2.47 $0.00
Disclosure

SEC source: 0001618835-22-000106 · wf-form4_165186780339870.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2032-05-04

F1 · derivative.exercise_price: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

F1 · shares: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Dr. Kamdar's board and committee services.

Read SEC document
June 18, 2021 Filed Jun 21, 2021 21:22 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 PurchaseCommon Stock 10,000 $1.17 $11,650.00
Disclosure

SEC source: 0001618835-21-000156 · wf-form4_162431053523492.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,287

Read SEC document
June 01, 2021 Filed Jun 1, 2021 16:40 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 ConversionSeries B Convertible Preferred Stock · Derivative 435,609 $0.00 $0.00
Disclosure

SEC source: 0000904454-21-000498 · edgar.xml · derivative · entry 6

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 435,609 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.exercise_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.expiration_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F1 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
June 01, 2021 Filed Jun 1, 2021 16:40 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 ConversionSeries A Convertible Preferred Stock · Derivative 1,293,243 $0.00 $0.00
Disclosure

SEC source: 0000904454-21-000498 · edgar.xml · derivative · entry 5

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,293,243 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.exercise_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.expiration_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F1 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
June 01, 2021 Filed Jun 1, 2021 16:40 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 ConversionSeries Seed Convertible Preferred Stock · Derivative 2,666,781 $0.00 $0.00
Disclosure

SEC source: 0000904454-21-000498 · edgar.xml · derivative · entry 4

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,666,781 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.exercise_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F2 · derivative.expiration_date: All outstanding shares of convertible preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The convertible preferred stock had no expiration date.

F1 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
June 01, 2021 Filed Jun 1, 2021 16:40 UTC Singular Genomics Systems, Inc. OMIC · Entity 82741 ConversionCommon Stock 4,395,633 Not disclosed Not disclosed
Disclosure

SEC source: 0000904454-21-000498 · edgar.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Domain Partners IX, L.P.

Disclosed balance after: 4,495,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

F1 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC and of One Partner Square Associates IX, LLC, the sole general partner of Domain Partners IX, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
May 12, 2021 Filed May 13, 2021 20:15 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 GrantStock option (right to buy) · Derivative 90,000 $0.00 Strike: $1.25 $0.00
Disclosure

SEC source: 0001618835-21-000110 · wf-form4_162093685845201.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2031-05-12

F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Kamdar's board and committee services.

Read SEC document
September 16, 2020 Filed Sep 18, 2020 23:43 UTC Vyome Holdings, Inc OBLN · Entity 1824 GrantStock Option (Right to Buy) · Derivative 27,250 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001214659-20-007965 · marketforms-49706.xml · derivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,250

Underlying: Common Stock · 27,250 shares

Expires 2030-09-16

F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Read SEC document
September 16, 2020 Filed Sep 18, 2020 23:43 UTC Vyome Holdings, Inc OBLN · Entity 1824 GrantStock Option · Derivative 27,250 $0.00 $0.00
Disclosure

SEC source: 0001214659-20-007965 · marketforms-49706.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,250

Underlying: Common Stock · 27,250 shares

Expires 2030-09-16

F1 · derivative.exercise_price: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock.

F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 20:35 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 PurchaseCommon Stock 5,000 $2.94 $14,700.00
Disclosure

SEC source: 0001618835-20-000196 · wf-form4_159233969119430.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,287

Read SEC document
May 12, 2020 Filed May 13, 2020 20:39 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 GrantStock option (right to buy) · Derivative 50,000 $0.00 Strike: $5.06 $0.00
Disclosure

SEC source: 0001618835-20-000134 · wf-form4_158940234764353.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-05-12

F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Kamdar's board and committee services.

Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:27 UTC Vyome Holdings, Inc OBLN · Entity 1824 PurchaseWarrants to Purchase Common Stock · Derivative 9,375 $4.00 Strike: $4.40 $37,500.00
Disclosure

SEC source: 0000904454-19-000602 · edgar.xml · derivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires 2024-08-06

F1 · price: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit.

Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:27 UTC Vyome Holdings, Inc OBLN · Entity 1824 PurchaseCommon Stock 12,500 $4.00 $50,000.00
Disclosure

SEC source: 0000904454-19-000602 · edgar.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,148

F1 · price: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit.

F2 · balance_after: The reported ownership reflects the one-for-ten reverse split of the Common Stock effected on July 24, 2019

F3 · ownership.direct: Includes 1,340 shares held jointly with the Reporting Person's mother. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, therein.

Read SEC document
July 23, 2019 Filed Jul 25, 2019 20:17 UTC Vyome Holdings, Inc OBLN · Entity 1824 GrantCommon Stock 78,125 $0.00 $0.00
Disclosure

SEC source: 0000904454-19-000580 · edgar.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,470

F1 · shares: Represents restricted stock units that will vest in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's annual meeting of stockholders immediately following the date of grant, subject to the Reporting Person's continued service through the applicable date.

F2 · ownership.direct: Includes 13,400 shares held jointly with the Reporting Person's mother. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, therein.

F3 · ownership.direct: Share amounts do not reflect the 1-for-10 reverse stock split that became effective after the grant date of the RSUs reported herein.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:38 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $6.05 $0.00
Disclosure

SEC source: 0000904454-19-000478 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-06-05

Read SEC document
May 22, 2019 Filed May 23, 2019 20:29 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 OtherCommon Stock 4,287 $0.00 $0.00
Disclosure

SEC source: 0000904454-19-000430 · edgar.xml · nonDerivative · entry 2

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,287

F3 · kind: Distribution-in-kind of shares by One Palmer Square Associates VII, LLC, pro rata to its members.

F3 · price: Distribution-in-kind of shares by One Palmer Square Associates VII, LLC, pro rata to its members.

Read SEC document
May 21, 2019 Filed May 23, 2019 20:29 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 SaleCommon Stock 655 $5.07 $3,320.85
Disclosure

SEC source: 0000904454-19-000430 · edgar.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Domain Associates, LLC

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.073 to $5.074. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The Reporting Person is a managing member of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by such entity, however, she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

Read SEC document
August 23, 2018 Filed Aug 27, 2018 21:38 UTC Vyome Holdings, Inc OBLN · Entity 1824 PurchaseCommon Stock 54,945 $1.82 $99,999.90
Disclosure

SEC source: 0000904454-18-000528 · edgar.xml · nonDerivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,345

F1 · ownership.direct: Includes 13,400 shares held jointly with the Reporting Person's mother. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, therein.

Read SEC document
June 13, 2018 Filed Jun 15, 2018 21:51 UTC Vyome Holdings, Inc OBLN · Entity 1824 GrantStock Option (Right to Buy) · Derivative 81,774 $0.00 Strike: $2.36 $0.00
Disclosure

SEC source: 0000904454-18-000426 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,774

Underlying: Common Stock · 81,774 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option vests as to 100% of the total shares on June 13, 2019, or the date of the Issuer's 2019 Annual Meeting, if sooner.

Read SEC document
May 08, 2018 Filed May 10, 2018 22:08 UTC Evofem Biosciences, Inc. EVFM · Entity 8607 GrantStock Option (Right to Buy) · Derivative 12,875 $0.00 Strike: $6.99 $0.00
Disclosure

SEC source: 0000904454-18-000341 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,875

Underlying: Common Stock · 12,875 shares

Expires 2028-05-08

F1 · derivative.exercise_date: The option vests in full on May 8, 2019, subject to the Reporting Person's continuous service to the Issuer.

Read SEC document
December 11, 2017 Filed Dec 13, 2017 16:58 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 Disposition to issuerCommon Stock 47,963 Not disclosed Not disclosed
Disclosure

SEC source: 0000904454-17-000727 · edgar.xml · nonDerivative · entry 1

DOMAIN ASSOCIATES · CIK 0001020733 · 10% owner

BLAIR JAMES C · CIK 0001024000 · 10% owner

DOVEY BRIAN H · CIK 0001207786 · 10% owner

TREU JESSE I · CIK 0001013425 · 10% owner

VITULLO NICOLE · CIK 0001196863 · 10% owner

Halak Brian K · CIK 0001354718 · 10% owner

Kamdar Kim P. · CIK 0001535065 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2 · kind: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F1 · price: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2 · price: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Read SEC document
June 20, 2017 Filed Jun 22, 2017 20:14 UTC Evofem Biosciences, Inc. NEOT · Entity 8607 GrantStock Option (Right to Buy) · Derivative 12,450 $0.00 Strike: $2.19 $0.00
Disclosure

SEC source: 0000904454-17-000452 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,450

Underlying: Common Stock · 12,450 shares

Expires 2027-06-20

F1 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer, the option vests on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's 2018 annual meeting of stockholders, or (iii) immediately prior to a change of control of the Issuer.

Read SEC document
June 06, 2017 Filed Jun 19, 2017 22:49 UTC Vyome Holdings, Inc OBLN · Entity 1824 GrantStock Option (Right to Buy) · Derivative 36,554 $0.00 Strike: $9.81 $0.00
Disclosure

SEC source: 0000904454-17-000446 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,554

Underlying: Common Stock · 36,554 shares

Expires 2027-06-06

F1 · derivative.exercise_date: The option vests as to 100% of the total shares on June 6, 2018, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Read SEC document
May 11, 2017 Filed May 15, 2017 21:08 UTC Evofem Biosciences, Inc. NEOT · Entity 8607 GrantStock Option (Right to Buy) · Derivative 63,500 $0.00 Strike: $2.15 $0.00
Disclosure

SEC source: 0000904454-17-000345 · edgar.xml · derivative · entry 1

Kamdar Kim P. · CIK 0001535065 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,500

Underlying: Common Stock · 63,500 shares

Expires 2027-05-11

F1 · derivative.exercise_date: The option vests monthly over a one-year period beginning on 2/15/2017, and will fully accelerate upon a change of control of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.